Cansino single dose Covid booster vaccine approved

30 Jun 2022 11:04pm
Solution Group Bhd, the Asean manufacturing partner of CanSino Biologics Inc in says the vaccine was approved for adults aged 18 years and older, regardless of the type of vaccine they received during their earlier Covid-19 vaccination. 123RF pic
Solution Group Bhd, the Asean manufacturing partner of CanSino Biologics Inc in says the vaccine was approved for adults aged 18 years and older, regardless of the type of vaccine they received during their earlier Covid-19 vaccination. 123RF pic
KUALA LUMPUR - The Health Ministry (MOH) has approved CanSino's single-dose Convidecia vaccine to be used as a heterologous booster with all Covid-19 primary vaccines in Malaysia.

Solution Group Bhd, the Asean manufacturing partner of CanSino Biologics Inc in a statement today said the vaccine was approved for adults aged 18 years and older, regardless of the type of vaccine they received during their earlier Covid-19 vaccination.

The statement also stated Convidecia will be given as a booster dose after at least three months of recipients receiving the second dose of their primary vaccination

"It is also the first and only Covid-19 vaccine from China to be included in the heterologous vaccination programme in Malaysia that can be administered as a mix-and-match with both Pfizer-BioNTech and AstraZeneca COVID-19 vaccines," the statement said.

In the same statement, SGB's deputy group managing director Datuk Dr Mohd Nazlee Kamal said recent studies in China showed the usage of Convidecia as a heterologous booster, via either intramuscular injection or using the inhaled version, generated greater neutralizing antibody responses.
Related Articles:


In addition, he said the vaccine's safety profile in real-life usage was also backed by the Mexican health authorities' Events Supposedly Attributable to Vaccination or Immunisation (ESAVI) Report released recently. - Bernama

More Like This